{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:04:52Z","timestamp":1792800292588,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Top Talent of Changzhou \u201cThe 14th Five-Year Plan\u201d High-Level Health Talents Training Project","award":["2022CZBJ051"],"award-info":[{"award-number":["2022CZBJ051"]}]},{"name":"the Clinical Research Project of Changzhou Medical Center of Nanjing Medical University","award":["CMCC202309"],"award-info":[{"award-number":["CMCC202309"]}],"id":[{"id":"https:\/\/ror.org\/059gcgy73","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Science and Technology Project of Changzhou Health Commission","award":["ZD202336"],"award-info":[{"award-number":["ZD202336"]}]},{"name":"the Changzhou Sci&Tech Program","award":["CJ20245027"],"award-info":[{"award-number":["CJ20245027"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04865-8","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:08:11Z","timestamp":1776924491000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of supplementing with Saccharomyces boulardii on vonoprazan\u2013amoxicillin dual therapy for naive Helicobacter pylori infection: a randomized controlled trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Zexuan","family":"Ji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingni","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghao","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangrong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"issue":"4","key":"4865_CR1","first-page":"397","volume":"39","author":"CS Goodwin","year":"1989","unstructured":"Goodwin CS, Armstrong JA, Chilvers T, et al. Transfer of campylobacter pylori and campylobacter mustelae to helicobacter gen. nov. as helicobacter pylori comb. nov. and helicobacter mustelae comb, nov., respectively. Int J Syst Evol MicroBiol. 1989;39(4):397\u2013405.","journal-title":"Int J Syst Evol MicroBiol"},{"issue":"8","key":"4865_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nrgastro.2013.96","volume":"10","author":"KM Fock","year":"2013","unstructured":"Fock KM, Graham DY, Malfertheiner P. Helicobacter pylori research: historical insights and future directions. Nat Rev Gastroenterol Hepatol. 2013;10(8):495\u2013500.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"Suppl 1","key":"4865_CR3","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1111\/hel.12256","volume":"20","author":"F Franceschi","year":"2015","unstructured":"Franceschi F, Gasbarrini A, Polyzos SA, et al. Extragastric diseases and helicobacter pylori. Helicobacter. 2015;20(Suppl 1):40\u20136.","journal-title":"Helicobacter"},{"key":"4865_CR4","doi-asserted-by":"publisher","unstructured":"Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. 2022;gutjnl\u20132022\u2013327745. https:\/\/doi.org\/10.1136\/gutjnl-2022-327745.","DOI":"10.1136\/gutjnl-2022-327745"},{"issue":"24","key":"4865_CR5","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","volume":"135","author":"L Zhou","year":"2022","unstructured":"Zhou L, Lu H, Song Z, et al. 2022 chinese national clinical practice guideline on helicobacter pylori eradication treatment. Chin Med J. 2022;135(24):2899\u2013910.","journal-title":"Chin Med J"},{"issue":"0","key":"4865_CR6","doi-asserted-by":"publisher","first-page":"0","DOI":"10.14218\/JTG.2023.00087","volume":"0","author":"NADA Elazazi","year":"2024","unstructured":"Elazazi NADA, Eltabbakh M, Hussein HM, et al. Efficacy of potassium-competitive acid blockers versus proton pump inhibitors in first- and second-line eradication regimens for helicobacter pylori in egyptian patients. J Translational Gastroenterol. 2024;0(0):0\u20130.","journal-title":"J Translational Gastroenterol"},{"issue":"24","key":"4865_CR7","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1056\/NEJMra1807761","volume":"381","author":"M Castells","year":"2019","unstructured":"Castells M, Khan DA, Phillips EJ. Penicillin Allergy. N Engl J Med. 2019;381(24):2338\u201351.","journal-title":"N Engl J Med"},{"issue":"12","key":"4865_CR8","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1111\/jgh.16761","volume":"39","author":"A Lin","year":"2024","unstructured":"Lin A, Lin Z, Liu Y, et al. Ten-day versus 14-day vonoprazan-amoxicillin high-dose dual therapy for Helicobacter pylori eradication in China: A multicenter, open-label, randomized study. J Gastroenterol Hepatol. 2024;39(12):2645\u201353.","journal-title":"J Gastroenterol Hepatol"},{"key":"4865_CR9","doi-asserted-by":"publisher","first-page":"175628482413098","DOI":"10.1177\/17562848241309870","volume":"17","author":"BG Zhou","year":"2024","unstructured":"Zhou BG, Guo MW, Zhang LJ, et al. Ten-day vonoprazan\u2013amoxicillin dual therapy versus 14-day esomeprazole\u2013amoxicillin dual therapy for first-line Helicobacter pylori eradication: a prospective multicenter randomized controlled trial. Therapeutic Adv Gastroenterol. 2024;17:17562848241309870.","journal-title":"Therapeutic Adv Gastroenterol"},{"issue":"4","key":"4865_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.14309\/ajg.0000000000002086","volume":"118","author":"HS Qian","year":"2023","unstructured":"Qian HS, Li WJ, Dang YN, et al. Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy. Am J Gastroenterol. 2023;118(4):627\u201334.","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"4865_CR11","first-page":"361","volume":"44","author":"YZ Jiang","year":"2024","unstructured":"Jiang YZ, Ma K, Cui C, Cao X, et al. Efficacy of different treatment duration of vonoprazan combined with low-dose amoxicillin in Helicobacter pylori eradication. Chin J Digestion. 2024;44(6):361\u20137.","journal-title":"Chin J Digestion"},{"issue":"9","key":"4865_CR12","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s00284-020-02053-9","volume":"77","author":"K Ka\u017amierczak-Siedlecka","year":"2020","unstructured":"Ka\u017amierczak-Siedlecka K, Ruszkowski J, Fic M, et al. Saccharomyces boulardii CNCM I-745: A Non-bacterial Microorganism Used as Probiotic Agent in Supporting Treatment of Selected Diseases. Curr Microbiol. 2020;77(9):1987\u201396.","journal-title":"Curr Microbiol"},{"issue":"8","key":"4865_CR13","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1128\/AEM.02201-06","volume":"73","author":"L Edwards-Ingram","year":"2007","unstructured":"Edwards-Ingram L, Gitsham P, Burton N, et al. Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae. Appl Environ Microbiol. 2007;73(8):2458\u201367.","journal-title":"Appl Environ Microbiol"},{"issue":"1","key":"4865_CR14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12876-025-03879-y","volume":"25","author":"YZ Jiang","year":"2025","unstructured":"Jiang YZ, Ma K, Cui C, et al. Effect of Saccharomyces boulardii supplementation to bismuth quadruple therapy on Helicobacter pylori eradication. BMC Gastroenterol. 2025;25(1):273.","journal-title":"BMC Gastroenterol"},{"issue":"10","key":"4865_CR15","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.3748\/wjg.v30.i10.1280","volume":"30","author":"VJ Dirjayanto","year":"2024","unstructured":"Dirjayanto VJ, Audrey J, Simadibrata DM. Vonoprazan-amoxicillin dual regimen with Saccharomyces boulardii as a rescue therapy for Helicobacter pylori: Current perspectives and implications. World J Gastroenterol. 2024;30(10):1280\u20136.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"4865_CR16","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1186\/s12876-024-03524-0","volume":"24","author":"J Yu","year":"2024","unstructured":"Yu J, Cui C, Ma K, et al. Effectiveness and safety of vonoprazan and amoxicillin dual regimen with Saccharomyces boulardii supplements on eradication of Helicobacter pylori. BMC Gastroenterol. 2024;24(1):430.","journal-title":"BMC Gastroenterol"},{"issue":"17","key":"4865_CR17","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJM198710223171717","volume":"317","author":"RD Mosteller","year":"1987","unstructured":"Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098.","journal-title":"N Engl J Med"},{"key":"4865_CR18","doi-asserted-by":"publisher","first-page":"175628482513548","DOI":"10.1177\/17562848251354868","volume":"18","author":"JY Zhang","year":"2025","unstructured":"Zhang JY, Chen JH, Huang YL, et al. Fourteen-day vonoprazan-amoxicillin dual therapy versus 14-day bismuth-based quadruple therapy for helicobacter pylori treatment: a randomized clinical trial. Therapeutic Adv Gastroenterol. 2025;18:17562848251354868.","journal-title":"Therapeutic Adv Gastroenterol"},{"issue":"3","key":"4865_CR19","doi-asserted-by":"publisher","first-page":"e70050","DOI":"10.1111\/hel.70050","volume":"30","author":"R Peng","year":"2025","unstructured":"Peng R, Cai P, Zhang Z, et al. Efficacy of three amoxicillin doses in vonoprazan dual therapy for helicobacter pylori eradication: a randomized noninferiority trial. Helicobacter. 2025;30(3):e70050.","journal-title":"Helicobacter"},{"issue":"18","key":"4865_CR20","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.3390\/foods13182866","volume":"13","author":"Z Tomi\u010di\u0107","year":"2024","unstructured":"Tomi\u010di\u0107 Z, \u0160ari\u0107 L, Tomi\u010di\u0107 R. Novel insights in the application of probiotic yeast saccharomyces boulardii in dairy products and health promotion. Foods. 2024;13(18):2866.","journal-title":"Foods"},{"issue":"10","key":"4865_CR21","first-page":"e46314","volume":"15","author":"S Gopalan","year":"2023","unstructured":"Gopalan S, Ganapathy S, Mitra M, et al. Unique properties of yeast probiotic saccharomyces boulardii CNCM I-745: a narrative review. Cureus. 2023;15(10):e46314.","journal-title":"Cureus"},{"issue":"8","key":"4865_CR22","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1007\/s00203-009-0491-x","volume":"191","author":"FS Martins","year":"2009","unstructured":"Martins FS, Silva AA, Vieira AT, et al. Comparative study of bifidobacterium animalis, escherichia coli, lactobacillus casei and saccharomyces boulardii probiotic properties. Arch Microbiol. 2009;191(8):623\u201330.","journal-title":"Arch Microbiol"},{"key":"4865_CR23","doi-asserted-by":"publisher","first-page":"776955","DOI":"10.3389\/fmed.2021.776955","volume":"8","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Yang Y, Aruna null, et al. Saccharomyces boulardii Combined With Quadruple Therapy for Helicobacter pylori Eradication Decreased the Duration and Severity of Diarrhea: A Multi-Center Prospective Randomized Controlled Trial. Front Med. 2021;8:776955.","journal-title":"Front Med"},{"issue":"3","key":"4865_CR24","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1097\/CEJ.0000000000000858","volume":"33","author":"O Sjomina","year":"2024","unstructured":"Sjomina O, Po\u013caka I, Suhorukova J, et al. Randomised clinical trial: efficacy and safety of H. pylori eradication treatment with and without Saccharomyces boulardii supplementation. Eur J cancer prevention: official J Eur Cancer Prev Organisation (ECP). 2024;33(3):217\u201322.","journal-title":"Eur J cancer prevention: official J Eur Cancer Prev Organisation (ECP)"},{"issue":"1","key":"4865_CR25","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1038\/s41467-024-48128-0","volume":"15","author":"MK Heavey","year":"2024","unstructured":"Heavey MK, Hazelton A, Wang Y, et al. Targeted delivery of the probiotic Saccharomyces boulardii to the extracellular matrix enhances gut residence time and recovery in murine colitis. Nat Commun. 2024;15(1):3784.","journal-title":"Nat Commun"},{"issue":"2","key":"4865_CR26","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1128\/IAI.71.2.766-773.2003","volume":"71","author":"S Dahan","year":"2003","unstructured":"Dahan S, Dalmasso G, Imbert V, et al. Saccharomyces boulardii interferes with enterohemorrhagic Escherichia coli-induced signaling pathways in T84 cells. Infect Immun. 2003;71(2):766\u201373.","journal-title":"Infect Immun"},{"issue":"2","key":"4865_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/BF01536771","volume":"35","author":"JP Buts","year":"1990","unstructured":"Buts JP, Bernasconi P, Vaerman JP, et al. Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sci. 1990;35(2):251\u20136.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"4865_CR28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1523-5378.2010.00751.x","volume":"15","author":"MJ Song","year":"2010","unstructured":"Song MJ, Park DI, Park JH, et al. The effect of probiotics and mucoprotective agents on PPI-based triple therapy for eradication of Helicobacter pylori. Helicobacter. 2010;15(3):206\u201313.","journal-title":"Helicobacter"},{"issue":"1","key":"4865_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12864-020-6665-2","volume":"21","author":"L Xu","year":"2020","unstructured":"Xu L, Surathu A, Raplee I, et al. The effect of antibiotics on the gut microbiome: a metagenomics analysis of microbial shift and gut antibiotic resistance in antibiotic treated mice. BMC Genomics. 2020;21(1):263.","journal-title":"BMC Genomics"},{"issue":"5","key":"4865_CR30","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1136\/gutjnl-2012-304066","volume":"63","author":"M Vivinus-N\u00e9bot","year":"2014","unstructured":"Vivinus-N\u00e9bot M, Frin-Mathy G, Bzioueche H, et al. Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut. 2014;63(5):744\u201352.","journal-title":"Gut"},{"issue":"1","key":"4865_CR31","doi-asserted-by":"publisher","first-page":"2575924","DOI":"10.1080\/19490976.2025.2575924","volume":"17","author":"Z Huang","year":"2025","unstructured":"Huang Z, Brot L, Fatouh R, et al. Saccharomyces boulardii CNCM I-745 mitigates antibiotic-induced gut microbiome functional alterations independently of the host. Gut Microbes. 2025;17(1):2575924.","journal-title":"Gut Microbes"},{"issue":"5","key":"4865_CR32","doi-asserted-by":"publisher","first-page":"e63893","DOI":"10.1371\/journal.pone.0063893","volume":"8","author":"E Distrutti","year":"2013","unstructured":"Distrutti E, Cipriani S, Mencarelli A, et al. Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. PLoS ONE. 2013;8(5):e63893.","journal-title":"PLoS ONE"},{"issue":"2","key":"4865_CR33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/j.1365-2036.2006.03179.x","volume":"25","author":"JL Tong","year":"2007","unstructured":"Tong JL, Ran ZH, Shen J, et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007;25(2):155\u201368.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"4865_CR34","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1365-2036.2010.04457.x","volume":"32","author":"H Szajewska","year":"2010","unstructured":"Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32(9):1069\u201379.","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"4865_CR35","doi-asserted-by":"publisher","first-page":"e12651","DOI":"10.1111\/hel.12651","volume":"24","author":"BG Zhou","year":"2019","unstructured":"Zhou BG, Chen LX, Li B, et al. Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication: A systematic review and meta-analysis with trial sequential analysis. Helicobacter. 2019;24(5):e12651.","journal-title":"Helicobacter"},{"issue":"1","key":"4865_CR36","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1186\/s12879-023-08896-4","volume":"23","author":"LH Liu","year":"2023","unstructured":"Liu LH, Han B, Tao J, et al. The effect of Saccharomyces boulardii supplementation on Helicobacter pylori eradication in children: a systematic review and meta-analysis of Randomized controlled trials. BMC Infect Dis. 2023;23(1):878.","journal-title":"BMC Infect Dis"},{"issue":"4","key":"4865_CR37","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/j.1523-5378.2007.00516.x","volume":"12","author":"M Cindoruk","year":"2007","unstructured":"Cindoruk M, Erkan G, Karakan T, et al. Efficacy and safety of saccharomyces boulardii in the 14-day triple anti-helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study. Helicobacter. 2007;12(4):309\u201316.","journal-title":"Helicobacter"},{"issue":"2","key":"4865_CR38","doi-asserted-by":"publisher","first-page":"e12953","DOI":"10.1111\/hel.12953","volume":"28","author":"J Guan","year":"2023","unstructured":"Guan J, Han Y, Wang M, et al. Impact of body size on efficacy of high-dose dual therapy for Helicobacter pylori eradication. Helicobacter. 2023;28(2):e12953.","journal-title":"Helicobacter"},{"issue":"2","key":"4865_CR39","doi-asserted-by":"publisher","first-page":"e12876","DOI":"10.1111\/hel.12876","volume":"27","author":"QQ Shao","year":"2022","unstructured":"Shao QQ, Yu XC, Yu M, et al. Rabeprazole plus amoxicillin dual therapy is equally effective to bismuth-containing quadruple therapy for Helicobacter pylori eradication in central China: A single-center, prospective, open-label, randomized-controlled trial. Helicobacter. 2022;27(2):e12876.","journal-title":"Helicobacter"},{"issue":"8","key":"4865_CR40","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1111\/bcp.14739","volume":"87","author":"A Soares","year":"2021","unstructured":"Soares A, L P P D P, Montanha MC, Alcantara CDS, et al. Pharmacokinetics of amoxicillin in obese and nonobese subjects. Br J Clin Pharmacol. 2021;87(8):3227\u201333.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"4865_CR41","first-page":"183","volume":"104","author":"RJ Baker","year":"1957","unstructured":"Baker RJ, Kozoll DD, Meyer KA. The use of surface area as a basis for establishing normal blood volume. Surg Gynecol Obstet. 1957;104(2):183\u20139.","journal-title":"Surg Gynecol Obstet"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04865-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04865-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:50:25Z","timestamp":1780617025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04865-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4865"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04865-8","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received approval from the Ethics Committee of the Third Affiliated Hospital of Nanjing Medical University (No. [2023] YLJSA016), and written informed consent was obtained from all enrolled patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"347"}}